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Abstract
This study reports on in vitro and in vivo tests that sought to assess the antifungal activity of
a newly developed magnetic carrier system comprising amphotericin B loaded onto the sur-
face of pre-coated (with a double-layer of lauric acid) magnetite nanoparticles. The in vitro
tests compared two drugs; i.e., this newly developed form and free amphotericin B. We
found that this nanocomplex exhibited antifungal activity without cytotoxicity to human uri-
nary cells and with low cytotoxicity to peritoneal macrophages. We also evaluated the effi-
cacy of the nanocomplex in experimental paracoccidioidomycosis. BALB/c mice were
intratracheally infected with Paracoccidioides brasiliensis and treated with the compound
for 30 or 60 days beginning the day after infection. The newly developed amphotericin B
coupled with magnetic nanoparticles was effective against experimental paracoccidioido-
mycosis, and it did not induce clinical, biochemical or histopathological alterations. The
nanocomplex also did not induce genotoxic effects in bone marrow cells. Therefore, it is rea-
sonable to believe that amphotericin B coupled to magnetic nanoparticles and stabilized
with bilayer lauric acid is a promising nanotool for the treatment of the experimental para-
coccidioidomycosis because it exhibited antifungal activity that was similar to that of free
amphotericin B, did not induce adverse effects in therapeutic doses and allowed for a reduc-
tion in the number of applications.
Author Summary
Lung fungal infections are caused by pathogens inhaled as spores which convert into inva-
sive yeast forms in the lungs. This type of infection can spread to other sites in the body
through the blood and lymphatic systems, sometimes leading to ulcerations and skin
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lesions. The drug of choice for treatment is Amphotericin B (AmB). AmB is a typical poly-
ene with broad-spectrum antifungal activity that encounters some use limitations because
of its side effects. We developed a magnetic carrier nanocomplex comprising of amphoter-
icin B loaded onto the surface of magnetite nanoparticles pre-coated with a double-layer
of lauric acid. We evaluated this approach for its antifungal activity against Paracocci-
dioides brasiliensis (strain Pb18) and its cytotoxicity in mammalian cell culture. We found
that this nanocomplex exhibited antifungal activity without cytotoxicity to human urinary
cells and low cytotoxicity to peritoneal macrophages. In vivo, the nanocomplex did not
induce genotoxic effects in bone marrow cells and was effective against experimental para-
coccidioidomycosis without inducing clinical, biochemical or histopathological
alterations.
Introduction
Paracoccidioidomycosis (PCM) is a systemic fungal infection caused by Paracoccidioides brasi-
liensis and Paracoccidioides lutzii [1]. PCM represents the most important systemic mycosis in
Central and South America. PCM significantly affects public health primarily targeting rural
workers with limited access to the health care. Like many fungal infections, the P. brasiliensis
pathogen is inhaled as spores and then germinates into the invasive yeast form in the lungs.
The infection spreads to other sites through the blood and lymphatic systems, such as the oral
mucous membranes and skin of the face, to cause several types of lesions [1–4]. Although PMC
is seldom observed as an opportunistic infection, PCM occasionally occurs in immune-com-
promised patients.
Amphotericin B (AmB) is a typical polyene with broad-spectrum antifungal activity and is
the drug of choice for the treatment of severe PCM or following the development of resistance
to other first line drugs. Unfortunately, AmB causes acute side effects (primarily kidney prob-
lems) following intravenous administration, which limits its clinical use [5–8]. Therefore, to
improve the therapeutic index of AmB and to reduce its toxicity for use in humans, new tech-
nological approaches have been employed in the engineering of recent formulations and drug
delivery; these approaches include lipid-based preparations such as AmB lipid complex, AmB
colloidal suspension, liposomal AmB, and AmB polymer [9–11]. Unfortunately, the clinical
use of the new formulations is limited due to cost, preventing broad access for patients who
depend upon public health care in many countries. As such, the development of new, afford-
able and effective antifungal delivery formulation with minimum cytotoxicity to human cells
would be beneficial to patient health and economically beneficial.
Nanobiotechnology has already begun to have important effects of healthcare. Superpara-
magnetic iron oxide (SPIO) particles, which are a typical class of nanosized magnetic material,
have been considered to be attractive magnetic probes for biological imaging and therapeutic
applications [12, 13]. The use of SPIO in drug delivery vehicles must address issues such as
drug-loading capacity, desired release profile, aqueous dispersion stability, biocompatibility
with cells and tissue, and retention of magnetic properties after interaction with macromole-
cules or modification via chemical reactions. Magnetic fluid (MF) samples primarily consist of
SPIO particles stably suspended in a carrier fluid and are of great importance due to their scien-
tific and biotechnological potentials. SPIO particles, particularly magnetite (Fe3O4) and
maghemite (γ-Fe2O3), are by far the most widely used magnetic nanoparticles (MNPs) in bio-
logical and medical applications [14]. The magnetic properties of MF samples and the huge
variety of MNP surface functionalizations, which allow for specificity and biocompatibility
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while preventing agglomeration and precipitation of the MNPs in suspension, provide oppor-
tunities for applications in different areas [15]. For example, nanosized particles engineered to
act as drug delivery systems that target the lungs have been extensively studied [16–22].
To investigate whether this approach reduces the side effects of AmB while simultaneously
providing controlled drug-delivery system, a nanosized magnetite surface-functionalized MF
sample with a bilayer of lauric acid conjugated with AmB (MFLB-AmB) was developed. The
present study aimed to evaluate this novel MFLB-AmB complex in terms of its antifungal activ-
ity against Paracoccidioides brasiliensis (strain Pb18) and its cytotoxicity using mammalian
cells. Additionally, this study aimed to evaluate the acute efficacy of MFLB-AmB in the treat-
ment of an intratracheal infection of paracoccidioidomycosis induced in mice.
Methods
Sample preparation
Magnetite (Fe3O4) nanoparticles were synthesized by a chemical co-precipitation reaction in
alkaline medium using an aqueous solution of Fe(II) and Fe(III) ions following a procedure
that has been described in the literature [23]. Briefly, the two aqueous-based solutions were
combined in a beaker, and concentrated ammonium hydroxide solution was added while stir-
ring. The black precipitate (Fe3O4) was separated from solution using a permanent magnet.
Then, lauric acid (LA; Sigma-Aldrich, St. Louis, MO, USA) was added to the black precipitate
for surface functionalization of the freshly precipitated magnetite nanoparticles. The mixture
was then heated at 90°C while stirring and water was added to adjust the volume. The magne-
tite nanoparticles were then spontaneously dispersed into the aqueous medium to yield a
water-based MF sample. Finally, the purified MF sample was autoclaved for sterilization at
121°C for 20 min. The stock MF sample, containing the LA bilayer-coated nanoparticles sus-
pended in aqueous medium, was labeled MFLB. The nanoparticle concentration within the
MFLB sample was estimated to be approximately 2.3×1015 particle/mL, whereas the iron con-
centration was 1.52 mg/mL. The association of AmB (Sigma-Aldrich, St. Louis, MO, USA)
onto the LA bilayer-coated nanoparticles was performed using a protocol similar to one that
has been described in the literature [24] in which AmB was dispersed in dimethyl sulfoxide
(DMSO; Mallinckrodt, USA) and mixed with the MFLB stock sample while stirring. The
resulting complex material system (MFLB-AmB) containing the AmB adsorbed onto the LA-
bilayer coated magnetite was separated from the free drug excess medium by magnetic separa-
tion and re-dispersed in sterile water. The magnetic nanoparticle concentration within the
MFLB-AmB complex was estimated to be approximately 2.6×1015 particle/mL, and the iron
concentration was found to be 1.74 mg/mL. The adsorbed AmB concentration was indirectly
determined by quantifying the excess drug (free AmB) using UV-Vis measurements (Spectra
Max M2, Molecular Device, USA) tuned to 411 nm. The measured AmB content incorporated
in the MFLB-AmB complex was found to be 1.02 mg/mL. Notably, the MFLB-AmB complex
incorporated iron (1.74 mg/mL) and AmB (1.02 mg/mL) within the same range of values per
unit volume. Similarly, the iron content in the MFLB sample (1.52 mg/mL) fell in the same
range. Indeed, the physical-chemical characteristics of the MFLB-AmB complex have been
investigated by Santos et al. [25] who reported on the molecular anchoring of AmB onto the
pre-coated magnetite nanoparticles. Briefly, the average particle diameters (standard deviation)
associated with samples of MFLB and MFLB-AmB as assessed via curve-fitting of the particle
size histograms obtained from transmission electron microscopy (TEM) were 6.0 (0.36) and
7.1 (0.28) nm, respectively. The difference we observed in the values of the deposited (TEM
sample holder) average particle diameters (6.0 and 7.1 nm) is consistent with the values
obtained for the hydrodynamic diameters of particles suspended within samples MFLB (77.7
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nm) and MFLB-AmB (84.8 nm) as estimated from dynamic light scattering measurements.
The larger hydrodynamic diameter observed for the MFLB-AmB sample was primarily due to
the adsorption of AmB onto the nanoparticle’s LA pre-coating layer. Notably, although the
magnetic nanoparticle, iron, and AmB concentrations within the MFLB-AmB complex were
similar to those of the sample used in the in vitro assays, the hydrodynamic diameter observed
for the MFLB-AmB sample used in the in vivo assays was greater (137.0 nm).
Cell and culture description
Paracoccidioides brasiliensis strain 18 (Pb18) was obtained from the fungal collection of the
Laboratory of Molecular Biology, Institute of Biological Science, University of Brasília (Brazil).
The Pb18 strain was cultured in liquid YPD medium (w/v: 2% peptone, 1% yeast extract, 2%
glucose) at 36°C in a rotary shaker (220 rpm). After 5 days of growth, a suspension of P. brasi-
liensis cells was prepared at a concentration of 1×107 viable cells/mL. Viability was determined
with Janus Green B vital dye (Merck, Darmstadt, Germany) and was always greater than 80%.
Pb18 was then used to test the antifungal activity of the MFLB-AmB complex.
Human mesangial cells (a renal cell line) were obtained from the American Type Culture
Collection (ATCC, USA) and maintained in the Laboratory of Nanobiotechnology, University
of Brasília (Brazil). These cells were grown at 37°C in a 5% CO2 atmosphere within Dulbecco's
modified Eagle's medium (DMEM) (Gibco, New York, NY, USA) at a pH of 7.4 supplemented
with 10% fetal calf serum (Life Technologies, Brasil), 100 U/mL penicillin and 100 μg/mL
streptomycin.
Peritoneal cells were obtained from the peritoneal cavities of 6-week-old BALB/c mice.
Briefly, the mice were anesthetized in a chamber with isoflurane and killed by CO2 gas. A small
incision was made in the abdominal skin while keeping the peritoneal membrane intact, and
20 mL of sterile, cold phosphate buffered saline (PBS, pH 7.4) was gently injected using a
25-mL syringe with a 20-gauge needle. Soft abdominal massage was performed to wash
(lavage) the intraperitoneal cavity. Using a Pasteur pipette, the lavage was slowly aspirated and
centrifuged at 1000 rpm for 10 min. The pellet was then washed three times with red blood cell
lysis buffer. The harvested peritoneal cells of the final pellet were plated with RPMI 1640
medium (Invitrogen) with 10% fetal bovine serum (FBS; Laborclin, Pinhais, PR, Brazil) and 1%
penicillin/streptomycin and incubated at 37°C under 5% CO2 for 3 hours. Non-adherent cells
were removed by washing with PBS, and adherent cells, i.e., macrophages, were re-incubated.
Evaluation of the in vitro antifungal activity
The antifungal activity of the MFLB-AmB complex was evaluated by assessing the minimum
inhibitory concentration (MIC) index. The MIC was defined as the lowest drug concentration
for which a 90% inhibition of growth in colony-forming units (CFUs). Fungal cell suspensions
(2×104 cells/100 μL) were incubated in RPMI 1640 medium supplemented with the MFLB-
AmB complex with AmB concentrations ranging from 0.125 to 8.0 μg/mL at 37°C. After 72
hours, the cell suspensions were removed from the media and transferred to Petri plates con-
taining brain heart infusion medium (BHI; HiMedia Laboratories, Mumbai, India) supple-
mented with 4% (v/v) horse serum (Gibco, New York, NY, USA), 5% (v/v) of the supernatant
from the culture filtrate of the isolate Pb192 and 40 mg/L gentamycin (Schering-Plough, USA).
The filtrate was prepared according to the methodology described by Singer-Vermes et al. [26].
The fungal cells were then incubated for five days at 37°C in a rotary shaker (220 rpm). The
control groups consisted of untreated fungal cells and fungal cells treated with the MFLB sam-
ple only. The MFLB content is described in terms of iron concentration and ranged from 0.21
to 13.64 μg/mL.
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In vitro MTT cytotoxicity assay
To evaluate the cytotoxicity of the MFLB-AmB complex using mammalian cells, we performed
an MTT assay as described by Wasan et al. [27]. The colorimetric MTT assay is based on the
capability of viable cells to reduce the yellow product MTT (3-(4,5)-dimethylthiazol-2-yl-
2,5-diphenyltetrazolium bromide) to a blue product (formazan) via a dye reduction reaction
that occurs only in the mitochondria of viable cells. Blue formazan crystals can be dissolved in
organic solvent, and the concentration can be quantified via spectrophotometric analysis.
Thus, the number of living cells is directly proportional to the intensity of the blue color.
Human mesangial cells and murine peritoneal macrophages (5×104 cells each) were treated
in culture medium supplemented with AmB alone or with the MFLB-AmB complex in which
the AmB concentrations ranged from 0.25 to 1.0 μg/mL. The treatment was performed at 37°C
for 6, 12 or 24 hours. The control groups consisted of untreated cells and cells treated with
MFLB only, with iron concentrations in the range of 0.42 to 204.70 μg/mL were quantified for
the latter. After treatment, the cells were incubated with MTT (0.5 mg/mL- Invitrogen, Grant
Island, NY, USA) for 4 hours at 37°C. Formazan crystals were dissolved in 200 μL of dimethyl
sulfoxide (DMSO). Cell viability was assessed by measuring the absorbance at 590 nm using a
microplate reader (SpectraMax M2, Molecular Device, USA). The results are expressed as
LC50s, the concentration required to reduce the cell population by half in a given time. The
LC50 values were estimated following probit analyses [28].
Animals and in vivo experimental design
Ethics statement. All animal handling and procedures were performed according to the
Guide for the Care and Use of Laboratory Animals published by the National Institutes of
Health, USA, and were approved by the Comitê de Ética no Uso Animal–CEUA (Animal Eth-
ics Committee of the University of Brasilia),–UnBDoc number 12155/2007.
Female BALB/c mice (6–8 weeks old) weighing 20–25 g were obtained from the Central
Animal Facility of the University of Brasilia (Brasília, Brazil). The animals were acclimatized to
the laboratory conditions for two weeks prior to the initiation of the study. They were housed
in plastic cages (6 animals/cage) at room temperature (20 ± 2°C) on a 12-hour light/dark cycle
with the lights on at 6 a.m. and provided free access to food and filtered water. After acclimatiz-
ing, the animals were anesthetized by intraperitoneal injection of ketamine (80 mg/kg) and
xylazine (10 mg/kg) in the same syringe following a final volume of 0.1 mL/30 g and their
necks were hyperextended to expose the trachea at the thyroid level. Animals were then
infected intratracheally with 3 × 106 P. brasiliensis yeast cells, according to Fernandes and
coworkers [29]. The establishment of disease was confirmed in one animal 30 days after infec-
tion, with lung histopathology revealing compact granulomas containing fungal cells, polymor-
phonuclear leukocyte aggregates, and fibrous tissue.
After inoculation with the pathogens, animals were randomly divided into the following
four experimental groups (n = 10) as detailed in Table 1: infected mice treated with PBS (posi-
tive control: PC group); infected mice treated with MFLB (MFLB group); infected mice treated
with AmB (AmB group); and infected mice treated with MFLB-AmB (MFLB-AmB group).
The treatment began 24 hours after inoculation with the pathogen. The MFLB, MFLB-AmB,
and PBS were administered every 3 days via nasal instillation, whereas AmB was administered
daily via intraperitoneal injection. The treatments lasted 30 or 60 days. Non-infected animals
treated with PBS served as the negative control (NC) group.
During the experimental time, mice were clinically examined and photographed for clinical
alterations. Additionally, the animals were monitored for weight gain or loss.
Magnetic Nanoparticle for Fungal Disease Treatment
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004754 June 15, 2016 5 / 18
Procedures and measurements
Twenty-four hours after each treatment, the animals were anesthetized with a mixture of xyla-
zine and ketamine according to the method described above, the body weights were measured,
and blood samples (1 mL) were collected via the ocular capillary and animals were killed by
cervical dislocation according to the AVMA Guidelines on Euthanasia [30]. The spleen, liver,
kidneys and lungs were removed for morphology analyses. The lungs were also removed to
determine the fungal burden and to quantify cytokine levels. Bone marrow cells were collected
to measure the rate of DNA fragmentation.
Biochemical and enzymatic analysis of blood
Blood samples were collected to assess the levels of total creatinine and urea as kidney function
markers and transferrin, aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) as liver function markers. The analyses were run on an ADVIA 2400 (Siemens, USA)
automated chemistry analyzer using the appropriate ADVIA chemistry reagents and protocols.
Total creatinine, urea, and transferrin were measured via colorimetric assays, and AST and
ALT were measured via optimized kinetic methods.
Histopathology analysis
To perform the morphological analyses, fragments of the organs were fixed with buffered para-
formaldehyde (4%) at room temperature for three hours, transferred to 70% ethanol, embed-
ded in paraffin using an automatic tissue processor (OMA DM-40, São Paulo, Brazil), and cut
to 5-μm thick slices on a Leica RM2235 manual microtome (Leica Microsystems, Nussloch,
Germany). The slides were stained with hematoxylin-eosin (H&E) for histological analyses. All
histological sections were photographed with a CCD camera with Axio Vision 40v 4.6.1.0 soft-
ware in a Zeiss Axioskop light microscope (Zeiss, Germany).
Lung tissue preparations to determine fungal burdens and for cytokine
assays
To determine the fungal burdens and quantify cytokines, such as interferon-gamma (IFN- γ),
interleukin-4 (IL-4), 10 (IL-10), and 12 (IL-12), in the lungs, lung fragments were weighed,
macerated, and homogenized in 1 mL cold, sterile PBS.
Table 1. Experimental design.
Group (n = 10) Treatment
PBS(μL)* MFLB (μg/μL)* AmB (μg/μL)** MFLB-AmB (μg/μL)*
Animals not infected (NC group) 80 - _ -
Animals with infection (PC group) 80 - _ -
Animals with infection (AmB group) _ - 40/100 -
Animals with infection (MFLB group) _ 80 - -
Animals with infection (MFLB-AmB group) _ - - 60,8/80
Female BALB/c mice uninfected (NC–negative control) and infected with Paracoccidioides brasiliensis, treated with PBS (PC–positive control), AmB
(Amphotericin B), MFLB-AmB (nanosized magnetite surface-functionalized with a bilayer of lauric acid conjugated with Amphotericin B) and MFLB
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Briefly, for the determinations of the fungal burdens, aliquots of the homogenized pulmo-
nary tissue were plated on Petri dishes containing Brain Heart Infusion medium (BHI, Acume-
dia, USA) supplemented with horse serum 4% (v/v), 5% (v/v) supernatant isolated from the
filtrated culture PB192, and 40 mg/L gentamicin. The colony-forming units (CFUs) were
counted seven days after plating and incubation at 37°C.
For the cytokine assays, aliquots of the homogenized tissue were centrifuged at 400 g for 20
min, and the cytokine analyses were performed on the supernatants. The Bradford method was
used for total protein quantification. The experimental protocols for the interferon-gamma
(IFN- γ), interleukin-4 (IL-4), 10 (IL-10), and 12 (IL-12) analyses were determined by manu-
facturers of the ELISA kits (e-Bioscience and BD, USA). These cytokines were quantified
because the presence of IFN- γ and IL-12 are associated with mild forms of disease in models
of pulmonary infection, and the presence of IL-10 and IL-4 are associated with the severe
forms of the disease [31].
DNA fragmentation measures
Bone marrow cells were collected from the femur bone and washed with 1 mL of fetal calf
serum. The collected material was centrifuged at 250 g for three minutes. The resulting pellet
was resuspended in cold ethanol (70%) to fix the cells. After 24 hours, the material was centri-
fuged at 250 g for three minutes and washed in PBS; resuspended in a 200 μL lysis buffer (0.1%
sodium citrate [Invitrogen, USA], 0.1% Triton X-100 [Merck, Germany]) containing propi-
dium iodide (20 μg/mL) in PBS (Sigma, USA). After 30 minutes and constant protection from
light, the DNA fragmentation was measured at 560–580 nm in a flow cytometer (BD FACSCa-
libur, USA).
Statistical analyses
The results are expressed as the means ± the SEMs of the different groups. The statistical analy-
ses were performed by one-way analyses of variance (ANOVA), and Tukey’s tests (GraphPad
PRISM 5.0, USA) were used when statistically significant differences were found. Differences
were considered significant at P< 0.05.
Results
Antifungal activity against Paracoccidoides brasiliensis (Pb18 strain) was determined via col-
ony-forming units (CFU) versus AmB concentration (μg/mL) added to the culture medium
(Fig 1). The data displayed is corrected for untreated controls (the Pb18 strain incubated with
RPMI 1640 medium only). The MIC indices for MFLB-AmB and AmB were 0.50 μg/mL and
0.25 μg/mL, respectively (Fig 1). In spite of the fact that the MIC for MFLB-AmB is the double
of that observed with AmB, it is clear that the Amphotericin B when conjugated to magnetic
nanoparticles stabilized with bilayer lauric acid maintains fungicidal activity.
The results of the LC50 tests of the MFLB-AmB nanocomplex are shown in Fig 2 using
human mesangial cells (Fig 2A) and mice peritoneal macrophages (Fig 2B). AmB was included
in the LC50 test for comparison. An LC50 test of MFLB with human mesangial cells was also
included. AmB concentration is denoted on the left vertical axis (Fig 2A and 2B), whereas the
iron concentration (for MFLB) is plotted on the right vertical axis (only in Fig 2B). After 6
hours of incubation with the MFLB-AmB nanocomplex, the human mesangial cells did not
exhibit remarkable cell death, and no LC50 could be calculated. After 12 hours of incubation,
the LC50 value for the MFLB-AmB complex (LC50 = 7225 μg/mL) was approximately six hun-
dred times higher than the LC50 value for the free AmB (LC50 = 11.9 μg/mL). Although the
LC50 value of the MFLB-AmB complex decreased to 89.98 μg/mL after 24 hours of incubation,
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it was still six-fold higher than the LC50 value of the free AmB (LC50 = 13.19 μg/mL) (Fig 2A).
Regarding the peritoneal macrophages, after 6 and 12 hours incubation with the MFLB-AmB
complex, we observed LC50 values of 309.3 and 166.7 μg/mL, respectively. Note that these val-
ues were four-fold higher than the LC50 values observed for free AmB, which were 85 μg/mL
(after 6 hours incubation) and 41.6 μg/mL (after 12 hours incubation). However, after 24 hours
of incubation with the peritoneal macrophages, the LC50 values of the MFLB-AmB complex
(LC50 = 83.43 μg/mL) and free AmB (LC50 = 104 μg/mL) were roughly the same (Fig 2B).
The MFLB-AmB complex was more cytotoxic to fungal cells than to mammalian cells (Fig
3). For the same MFLB-AmB complex concentration, the mesangial cell viability was higher
than the macrophage viability. Additionally, the mesangial cells were more resistant at lower
MFLB-AmB complex concentrations, although cytotoxicity was enhanced at higher
MFLB-AmB concentrations (Fig 3).
Fig 1. MIC determination of free AmB and MFLB-AmB against liquid suspensions of Paracoccidioides brasiliensis. Fungal burden as
assessed by Colony Forming Units (CFU) in Paracoccidioides brasiliensis strain 18 (Pb18) (2 x 104 cells/mL) while incubated in RPMI 1640
medium at 37°C for 72 hours with AmB or MFLB-AmB, as a function of amphotericin B, or MFLB, as a function of iron concentration. After 72 hour
incubation, cell suspensions were plated on BHI (brain heart infusion) media, supplemented with 4% (v/v) of horse serum, 5% (v/v) of the
supernatant from the culture filtrate of isolate Pb192 and 40 mg/L gentamycin, and then incubated for five days at 37°C in a rotary shaker (220
rpm).(AmB = amphotericin B, MFLB-AmB = nanosized magnetite surface-functionalized with a bilayer of lauric acid conjugated with amphotericin
B, MFLB = nanosized magnetite surface-functionalized with a bilayer of lauric acid).
doi:10.1371/journal.pntd.0004754.g001
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Fig 2. Cytotoxicity of AmB, MFLB-AmB or MFLB toward humanmesangial cells and isolated mouse peritoneal macrophages. Concentration of
amphotericin B (left vertical axis) in AmB or MFLB-AmB or iron concentration (right vertical axis–panel B) in MFLB required to reduce by half the cell
population (LC50) at different time windows, A) human mesangial cells and B) mice peritoneal macrophage cells 5×10
4 cells were treated in culture
medium with AmB alone or with the MFLB-AmB complex rangin AmB concentration from 0.25 to 1.0 μg/mL at 37°C for 6, 12 or 24 hours. After indicated
times, cells were incubated with MTT (0.5 mg/mL- Invitrogen, Grant Island, NY, USA) for 4 hours at 37°C. Formazan crystals were dissolved in 200 μL
of dimethyl sulfoxide (DMSO). Cell viability was assessed by measuring the absorbance at 590 nm, using a microplate reader. LC50 values were
estimated following Probit Analyses. (AmB = amphotericin B, MFLB-AmB = nanosized magnetite surface-functionalized with a bilayer of lauric acid
conjugated with amphotericin B, MFLB = nanosized magnetite surface-functionalized with a bilayer of lauric acid treated at the same corresponding iron
concentration of MFLB-AmB, ranging from 0.42 to 204.70 μg of Fe/mL).
doi:10.1371/journal.pntd.0004754.g002
Fig 3. MFLB-AmB complex wasmore cytotoxic to fungal cells than to mammalian cells. Comparison of in vitro cytotoxicity of the
MFLB-AmB (nanosized magnetite surface-functionalized with a bilayer of lauric acid conjugated with amphotericin B) against fungal
(Paracoccidoides brasiliensis strain 18 –Pb18) and mammalian cells (human mesangial cells and peritoneal macrophage). Fraction survival of
indicated cells versus log concentration of MFLB-AmB (μg/mL).
doi:10.1371/journal.pntd.0004754.g003
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The efficacy of MFLB-AmB against strain Pb18 was also investigated in vivo using a mouse
model of paracoccidioidomycosis (PCM). H&E stained sections of lungs harvested from ani-
mals from the PC group (Fig 4B) and MFLB group (Fig 4C) had lungs with fungal cells with
granulomas and inflammatory cells near the blood vessels and the bronchial tree. The lung tis-
sue sections from the uninfected animals (NC group) exhibited typical appearances with no
histological lesions (Fig 4A). Following acute treatment with the MFLB-AmB nanocomplex or
free AmB,resulted in a 100% absence of detection in fungal load as observed via lung sections
Fig 4. Histological appearance of female BALB/c mice lungs tissue hematoxylin and eosin-stained
sections.Representative images are shown from (a) uninfected animal (b) infected animal with PBS treatment
(c) infected animal treated with MFLB (d) infected animal treated with AmB and (e & f) infected animal treated
with MFLB-AmB. Thick arrows in (b) and (c) indicate the presence of fungal cells inside granuloma. Asterisks in
(b) indicate inflammatory focus; thin arrow in (c), (e) and (f) indicate nanoparticle aggregation. Portions of lungs
were fixed in buffered paraformaldehyde 4% at room temperature for three hours followed by routine paraffin
embedded procedure using an automatic tissue processor. Tissue sections of 5 μm of thickness were obtained
with a manual microtome. (AmB = amphotericin B, MFLB-AmB = nanosized magnetite surface-functionalized
with a bilayer of lauric acid conjugated with amphotericin B, MFLB = nanosized magnetite surface-functionalized
with a bilayer of lauric acid; animals were infected with Paracoccidioides brasiliensis).
doi:10.1371/journal.pntd.0004754.g004
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after 30 days of treatment (Fig 4D–4F) and CFU in lung homogenates after 60 days of treat-
ment (Fig 5). However, the animals from the AmB groups exhibited inflammatory cells near
the blood vessels and the bronchial tree (Fig 4D).
To evaluate the basis of the histological lesion category, we quantified cytokines such as
interferon-gamma (IFN- γ), interleukin-4 (IL-4), 10 (IL-10), and 12 (IL-12) in the lung homog-
enates. Thirty days after treatment all interleukins levels reveal changes due to infection; while
IFN-γ, IL-4, and IL-12 decreased (PC< NC), IL-10 increased (PC> NC). The two antifungal
treatments (MFLB-AmB and AmB) showed different trends when compared with the PC
(Table 2). The AmB treatment increased the levels of IFN-γ, IL-4 and IL-12 compared to PC
Fig 5. Fungal burden as assessed by CFU frommice lungs treated with AmB, MFLB-AmB, andMFLB. Lung fragments were
weighed, macerated and homogenized in 1 mL cold, sterile PBS. Part of homogenized pulmonary tissue was plated on Petri dishes
containing BHI (Brain Heart Infusion) medium, supplemented with 4% (v/v) horse serum, 5% (v/v) supernatant isolated from the
infiltrated culture Pb192, and 40 mg/L gentamicin. CFU per gram of lung were determined seven days after plating with incubation at
37°C. Negative Control Group = animals uninfected; Positive Control, MFLB, AmB and MFLB-AmB Groups = animals infected with
Paracoccidioides brasiliensis; (AmB = Amphotericin B; MFLB-AmB = nanosized magnetite surface-functionalized with a bilayer of
lauric acid conjugated with AmB; MFLB = nanosized magnetite surface-functionalized with a bilayer of lauric acid).
doi:10.1371/journal.pntd.0004754.g005
Table 2. Cytokine levels, as determined by ELISA, in lung homogenates prepared from female BALB/c mice with AmB, MFLB-AmB, andMFLB.
Group IFN-γ (pg/mg) IL-4 (pg/mg) IL-10 (pg/mg) IL-12 (pg/mg)
30 days 60 days 30 days 60 days 30 days 60 days 30 days 60 days
NC 919±179B 922±200B 200±14B 169±22B 12.3 ±2.4B 14.0 ±3.0B 1546±234A 1521±378B
PC 213±71C 2316±580A 90±12C 439±31A 64.5 ± 12.8A 167 ±5.4A 554±109B 2987±580A
AmB 1515±224A 426±172C 768±184A 200±47B 103.2±15.8A 205±113A 2132±323A 634±74C
MFLB-AmB 99±30C 919±288B 2.3±0.3D 265±78B 94.7±36.5A 70 ±4.2A 234±45C 1432±287B
MFLB 470±130C 922±341B 130±51C 254±40B 56.7±24.0A 123 ±27A 679±67B 1580±322
NC Group = animals uninfected; Positive Control, MFLB, AmB and MFLB-AmB Groups = animals infected with Paracoccidoides brasiliensis;
AmB = amphotericin B; MFLB-AmB = nanosized magnetite surface-functionalized with a bilayer of lauric acid conjugated with AmB; MFLB = nanosized
magnetite surface-functionalized with a bilayer of lauric acid
Different letters denote signiﬁcant differences between treatments (Tukey, p < 0.05) inside the same column.
doi:10.1371/journal.pntd.0004754.t002
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mice (AmB> PC). MFLB-AmB treatment decreased the levels of IL-4 and IL-12 in an opposite
direction compared to PC treatment (MFLB-AmB< PC) while keeping the IFN-γ level
unchanged (MFLB-AmB = PC). As far as the IFN-γ level is concerned, MFLB did not change
the effects of AmB while conjugated in one single structure (AmB =MFLB-AmB). However,
compared to MFLB, the levels of IL-4 and IL-12 were reduced after treatment with AmB-MFLB
(MFLB>MFLB-Amb), indicating that inclusion of MFLB into the MFLB-AmB complex does
modulate the AmB alone treatment effects on IL-4 and IL-12 levels (Table 2).
Sixty days after treatment the infected animals (PC) showed increased levels of all interleu-
kins compared with uninfected animals (NC). Both antifungal agents (MFLB-AmB and AmB)
reduced the IFN-γ, IL-4, and IL-12 levels compared with the PC (Table 2). However, we found
that reduction of IFN-γ and IL-12 levels induced by the AmB treatment was significantly
higher than that induced by the MFLB-AmB treatment. Comparison between treatments per-
formed with MFLB-AmB and MFLB showed that levels of all interleukins did not differ
(MFLB = MFLB-AmB), indicating that in the long term the presence of MFLB did not interfere
with the AmB action (Table 2). The levels of IL-10 were not affected by any treatment
(MFLB-AmB = AmB = PC), either after 30 or 60 days (Table 2).
We also evaluated whether the MFLB-AmB complex induced toxicity in the kidneys, liver,
and spleen. The spleen, liver, and kidneys of the animals treated with the MFLB-AmB complex
exhibited no morphologic abnormalities. Examination of urea and creatinine values as markers
of kidney function and transferrin, aspartate aminotransferase (AST) and alanine aminotrans-
ferase (AST) as markers of liver functions were also performed. MFLB-AmB complex induced
significant increases in urea levels after 60 days of treatment when compared to the NC group.
The same occur in AmB and MFLB-AmB in urea levels after 60 days of treatment when com-
pared to the PC group. (Table 3). MFLB induce a significant decrease in urea levels after 60
days of treatment when compared to NC group.
The treatment AmB, MFLB-AmB or MFLB doesn’t show significantly different in creatinine
and transferrin levels after 30 and 60 days when compared to NC and PC groups.
MFLB induce a significant decrease in AST levels after 30 days of treatment when compared
to the NC group. But after 60 days of treatment that difference is not significant. The same
occur in ALT levels with MFLB treatment, after 30 days of treatment induce significant
increase the levels when compared to the NC group. But after 60 days of treatment that differ-
ence is not significant.
Table 3. Biochemical and enzymatic analysis of blood from female BALB/c mice after treatment with AmB, MFLB-AmB, and MFLB for 30 or 60
days.
Groups Urea(mg/DL) Creatinine (mg/DL) AST (UI/L) ALT (UI/L) Transferrin
30 days 60 days 30 days 60 days 30 days 60 days 30 days 60 days 30 days 60 days
NC 49 ±7.4 57±6.6C,B 0.22±0.1 0.22±0.05 101±20.28A 83±3.31A 7±2.2 12.25±1.70 222±2.38B 220±3.7
PC 48±3.5 48±5.7C 0.3±0.1 0.23±0.05 128±24.84A,B 71±0.57B 10±1.6 6.66±2.51 227±3.60A,B 217±10.5
AmB 62±9 61±4.0B 0.24±0.1 0.23±0.11 133±22.65A,B 85±8.00A,B 10±0.8 10.33±2.51 225±12.9A,B 233±5.5
MFLB-AmB 53±8.7 79±1.0A 0.27±0.05 0.30±0 97±16.34A,B 114±2.30A,B 9±3.2 10.00±0 234±4.12A 232±0.6
MFLB 60±5.6 43±1.5D 0.30±0 0.30±0 69±0.57B 91±20.51A,B 12±1.7 9.66±0.57 226±5.85A,B 227±10.2
NC Group = animals uninfected; Positive Control, MFLB, AmB and MFLB-AmB Groups = animals infected with Paracoccidoides brasiliensis;
AmB = amphotericin B; MFLB-AmB = nanosized magnetite surface-functionalized with a bilayer of lauric acid conjugated with amphotericin B;
MFLB = nanosized magnetite surface-functionalized with a bilayer of lauric acid
Different letters denote signiﬁcant differences between treatments (Tukey, p < 0.05) inside the same column. Treatments without lettering are not
signiﬁcantly different inside the same column.
doi:10.1371/journal.pntd.0004754.t003
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Treatment with the MFLB-AmB nanocomplex did not induce significant DNA fragmenta-
tion in the bone marrow cells of the mice (Fig 6). Additionally, no animals exhibited changes in
appearance or losses of body weight during the treatments.
Discussion
Our findings revealed that a newly developed MFLB-AmB nanocomplex was effective against an
experimental model of paracoccidioidomycosis. The MFLB-AmB complex eliminated the fungal
burden in the lungs and was less toxic than free (unbound) AmB both in vitro and in vivo.
Although free AmB was more effective against Pb18 with an MIC index of 0.25 μg/mL, the
MFLB-AmB complex exhibited considerable antifungal activity with MIC index of 0.50 μg/mL
(see Fig 1). No antifungal activity was observed at any MFLB concentrations tested. Addition-
ally, the cytotoxicity of the MFLB-AmB nanocomplex in mesangial cells was significantly
lower than that of the free AmB, indicating that when AmB is adsorbed onto the LA-bilayer-
coated magnetite, the toxic side effect AmB toward mammalian urinary cells may be alleviated.
Similarly, low toxicity of MFLB-AmB to mice peritoneal macrophages was observed. Cell via-
bility subsequent to nanoparticle uptake is expected to be time-dependent. Initially, cells have
to deal with the sudden exposure and internalization of nanoparticles, followed by a period of
6–10 hours of cellular growth as the cells resume their cellular activities, and the cell number
either stabilizes or is reduced due to cell toxicity [32]. We found that free AmB and adsorbed
AmB (MFLB-AmB) induced cytotoxicity similar to that of MFLB. Indeed, the enhanced uptake
of surface-coated nanosized iron oxide particles by macrophages has previously been demon-
strated [33, 34]. In this regard, cell uptake is linked to particle size, time dependence, and con-
centration dependence [33].
According to the literature, fungal cells are more susceptible to AmB than cultured animal
cells. This characteristic is due to the specific interaction of AmB with ergosterol, a typical ste-
roid found uniquely in the fungal cell wall, which leads to the formation of pores through the
lipid membrane and consequent cell death [35–39]. Although AmB has a greater affinity for
ergosterol, it also binds to the cholesterol found in mammalian cell membranes, which is
believed to account for its toxicity in animals and humans, particularly renal cells [38, 40–42].
Although only free (unbound) AmB has been reported to bind to ergosterol [38], in the
present study, we found that AmB adsorbed onto magnetic nanoparticles (MFLB-AmB)
Fig 6. DNA fragmentation in bonemarrow cells frommice treated with AmB, MFLB-AmB or MFLB.
Female BALB/c mice uninfected (NC–negative control) and infected with Paracoccidioides brasiliensis,
treated with PBS (PC–positive control), AmB (Amphotericin B), MFLB-AmB (nanosized magnetite surface-
functionalized with a bilayer of lauric acid conjugated with Amphotericin B) and MFLB (nanosized magnetite
surface-functionalized with a bilayer of lauric acid) for 30 or 60 days.
doi:10.1371/journal.pntd.0004754.g006
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maintained its antifungal activity. Recently, Santos et al. [25] suggested that AmB grafted onto
lauric acid (bilayer coated) pre-coated magnetite nanoparticles results in hydrophilic portions
of AmB facing outwards, making AmB available to interact with the cell membrane forming
the trans-membrane channels. While AmB incorporated into the MFLB-AmB nanocomplex
exhibited an MIC index (0.50 μg/mL) that was two times higher than that of free AmB
(0.25 μg/mL), the MIC value of MFLB-AmB nanocomplex is consistent with the MIC values of
0.03 to 1.0 μg/mL that have been reported in in vitro studies [43–45].
Indeed, engineering of nanosized drug carrier platforms based on iron oxide nanoparticles
has attracted significant attention because these systems exhibit relatively low cell and tissue
toxicities, are inexpensive to produce, are efficient, and immobilize biological materials at their
surface [39]. Despite the good colloidal stability achieved by MF samples, it has been shown
that a small fraction of the suspended magnetic particles tends to aggregate; however, aggrega-
tion can be reduced by various surface stabilizers [46]. Thus, the association of AmB with the
surface pre-functionalized magnetic nanoparticles might represent an excellent material plat-
form for the treatment of chronic forms of fungal disease [25]. In the present study, we used
AmB associated with an LA-bilayer that coated magnetite (Fe3O4) nanoparticles. LA is known
to stimulate the immune system by activating and releasing interleukin 2 [47]. Moreover,
nanoparticles are known to enhance cellular uptake of the loaded drugs by various mecha-
nisms, including protecting the drug from degradation. The efficacy of AmB is compromised
by the high occurrences of adverse effects associated with the toxicity of the drug in humans.
Therefore, we evaluated the cytotoxicity of the MFLB-AmB complex in mammalian cells via
an MTT assay. We found that MFLB-AmB has relative low cytotoxicity, as demonstrated by
higher LC50 values, in peritoneal macrophages and that the cytotoxicity was time and concen-
tration dependent. However, the cytotoxicity of MFLB-AmB was similar to those of free AmB
and MFLB.
Furthermore, morphological analyses of the livers, spleens, and kidneys of the infected ani-
mals treated with MFLB-AmB exhibited no tissue alterations. Biochemical tests are widely
used to diagnose animal diseases and to monitor treatment responses. Literature indicates that
treatment with free (unbound) AmB results in increased creatinine and urea in the serum due
to renal vasoconstriction and a reduction of the glomerular filtration rate [48, 49]. Moreover,
there are experimental data that suggest that free (unbound) AmB might influence the meta-
bolic capacity of the liver [50]. Levels of certain liver enzymes in the blood can be indicative of
liver injury. Under normal circumstances, these enzymes primarily reside within the cells of
the liver, but when the liver is injured by any cause, these enzymes spill into the bloodstream.
Among the most sensitive and widely used liver enzymes are the aminotransferases, including
aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Transferrin is also a
plasma protein that is produced by liver and transports iron through the blood to the liver,
spleen and bone marrow; controlling the level of free iron in biological fluids. The level of
transferrin in the plasma decreases in conditions of liver and kidney diseases. Thus, we mea-
sured the serum levels of urea and creatinine as biomarkers of kidney functions and the levels
of transferrin, AST, AST as biomarkers of liver injury. In the present study, we observed a lack
of significant differences in all of these markers following treatment with MFLA-AmB, relative
to the positive control (infected mice treated with PBS). These findings demonstrate the safety
of our MFLA-AmB nanocomplex at the doses tested in this experiment.
Although its potential toxicity had previously been detected in clinical trials, free AmB in
this study failed to elicit any cytotoxic effects in the kidneys, which might be related to the
route of administration. Animals received intraperitoneal injections of free AmB daily for 30 or
60 days. This route was chosen to test for acute drug toxicity as the detoxifying effects of the
entero-hepatic system would make the evaluation of a novel material via the gastrogavage
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PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004754 June 15, 2016 14 / 18
route difficult. MFLB-AmB and MFLB were administered by nasal instillation because, com-
pared to conventional oral therapy, inhalation drug delivery has been proven to be superior in
terms of delivering high payloads of drug into the lungs [51]. Collectively our results demon-
strate that the MFLB-AmB complex reduced the adverse effects and increased the therapeutic
effects of AmB. Notably, the MFLB-AmB complex was administered to the animals every three
days, while the free AmB was administered daily to the animals, similar to clinical trials.
Although morphology is a phenotypic aspect that is particularly important in toxicity stud-
ies, a more detailed analysis that allows for the early detection of the effects of a substance
should be considered. Such early detection could involve the analysis of DNA fragmentation.
Therefore, we also performed a genotoxicity test with bone marrow cells to determine whether
MFLB-AmB induced DNA damage. Bone marrow tissue is easy to isolate and process, highly
vascularized tissue and contains a population of rapidly cycling cells that is routinely used in
DNA damage tests. The MFLB-AmB complex did not induce DNA fragmentation. These data
reinforce those obtained from the histopathology analyses; i.e., the MFLB-AmB complex was
toxic only to the cells of the fungus P. brasiliensis.
In both the human and the experimental models, cellular immunity is the primary defense
mechanism against paracoccidioidomycosis [52]. Thus, we quantified cytokines, including
interferon-gamma (IFN- γ), interleukin-4 (IL-4), 10 (IL-10), and 12 (IL-12), in the lungs. In a
general, except for IL-10, all the other interleukin levels were reduced after 30 days of
MFLB-Amb treatment. However, interleukin levels returned to the same as observed in unin-
fected animals after 60 days of MFLB-Amb treatment. It is interesting to note that it is exactly
the opposite that occurs with the Amb animals group. Since both treatments (Amb and
MFLB-Amb) successfully treated the paracoccidioidomycosis infection, it is possible that the
decrease total dose of MFLB-AmB aided in decreasing the time for the levels of measured inter-
leukins to return to the normal levels. Surely possible explanations exist for these results and
futures studies are necessary to clarify this point.
According to Fortes and coworkers [31], increased levels of IL-10 and IL-4 are associated
with the severe form of the disease, while IFN- γ and IL-12 are associated with mild forms of
the disease. In the present study, mice treated with the MFLB-AmB nanocomplex lacked signif-
icant changes in IL-10 levels but reduced IL-4 after 30 days compared to the positive controls.
These results are interesting because in humans the humoral immune response is not protec-
tive against paracoccidioidomycosis; rather, a response correlates with a poor prognoses for
patients suffering from the disease. MFLB-AmB also reduced IL-12 and IFN-γ after 60 days
compared to the positive control. During the course of a paracoccidioidomycosis infection,
CD4+ lymphocytes synthesize IFN-γ and IL-12, which hinder the spread of the fungus. A pos-
sible explanation for both IFN-γ and IL-12 being low following MFLB-AmB is that treatment
eliminated the fungal burden from the lungs; if there is no infection, the immune system does
not need to synthesize these molecules.
In conclusion, our findings support the claim that when AmB is coupled to magnetic nano-
particles stabilized with bilayer lauric acid, as with our novel MFLB-AmB nanocomplex, AmB
retains its efficacy against paracoccidioidomycosis without inducing acute hepatotoxic and
nephrotoxic effects. Treatment in the form of MFLB-AmB also appears to allow for a reduction
in the number of applications. Thus, this nanocomplex represents a promising alternative for
the treatment of Paracoccidioides brasiliensis.
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